CeriBell, Inc. (NASDAQ:CBLL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received a consensus rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $24.6667.

CBLL has been the subject of several recent analyst reports. TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Canaccord Genuity Group boosted their price objective on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. BTIG Research reiterated a “buy” rating and set a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. Finally, JPMorgan Chase & Co. lowered their price target on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th.

Insider Transactions at CeriBell

In related news, CEO Xingjuan Chao sold 79,000 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $21.27, for a total transaction of $1,680,330.00. Following the completion of the transaction, the chief executive officer directly owned 741,248 shares of the company’s stock, valued at approximately $15,766,344.96. This trade represents a 9.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William W. Burke sold 32,728 shares of CeriBell stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $22.02, for a total transaction of $720,670.56. Following the completion of the sale, the director owned 17,391 shares in the company, valued at approximately $382,949.82. This represents a 65.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 305,973 shares of company stock valued at $6,425,950. 20.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CeriBell

A number of hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its holdings in CeriBell by 41.4% during the 4th quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after buying an additional 854 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares in the last quarter. Deutsche Bank AG increased its position in CeriBell by 1.7% in the fourth quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock worth $1,868,000 after purchasing an additional 1,393 shares during the last quarter. Finally, Royal Bank of Canada raised its stake in CeriBell by 10.8% during the fourth quarter. Royal Bank of Canada now owns 15,588 shares of the company’s stock valued at $342,000 after purchasing an additional 1,514 shares in the last quarter.

CeriBell Stock Performance

NASDAQ CBLL traded down $0.59 on Monday, reaching $18.08. 61,820 shares of the stock were exchanged, compared to its average volume of 345,463. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13. CeriBell has a one year low of $10.01 and a one year high of $24.68. The firm has a market capitalization of $680.62 million, a PE ratio of -12.38 and a beta of 1.03. The company’s 50-day simple moving average is $21.11 and its two-hundred day simple moving average is $16.32.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The firm had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. Analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.